PridCor's SHIELD Study: Combination Antiviral Bet in Long COVID Faces Crowded, Unproven Field

PridCor Advances SHIELD Study for Long COVID Towards Enrollment

PridCor Therapeutics announced the first payment under its clinical trial agreement with the Icahn School of Medicine at Mount Sinai for the SHIELD Study and the ordering of study drug, signaling the advancement of its Phase 2 trial for Long COVID towards enrollment. The randomized, double-blind, placebo-controlled study (NCT07597902) plans to enroll approximately 150 adults aged 18 to 65. It will evaluate a combination antiviral regimen, with the primary endpoint being the EQ-5D-5L visual analogue scale, a patient-reported rating of overall health. This development follows a peer-reviewed case series published in Frontiers in Immunology, which concluded that a randomized, placebo-controlled trial was the necessary next step.

• PridCor Therapeutics has made significant operational progress for the SHIELD Study, including the first payment under its clinical trial agreement with the Icahn School of Medicine at Mount Sinai and the ordering of study drug. These actions are critical steps in preparing for patient enrollment in the Phase 2 trial, which will be conducted at Mount Sinai’s Cohen Center for Recovery from Complex Chronic Illness.
• The SHIELD study is designed as a randomized, double-blind, placebo-controlled Phase 2 trial, aiming to enroll approximately 150 adults aged 18 to 65 with Long COVID. The investigational regimen combines valacyclovir, celecoxib, and a 25-day course of nirmatrelvir/ritonavir, which will be evaluated against a matched placebo. The primary endpoint for the study is the EQ-5D-5L visual analogue scale, a patient-reported measure of overall health.
• The scientific foundation for the SHIELD study stems from an open-label case series published in Frontiers in Immunology in January 2026. This prior research, though limited by its small, open-label, and single-site nature, indicated promising reductions in fatigue among Long COVID patients treated with a three-drug regimen. The authors of the case series explicitly recommended a randomized, placebo-controlled trial to validate these observations, which the SHIELD study is now designed to fulfill.

SHIELD Study: Unpacking the Phase 2 Design for Long COVID

Several randomized and observational trials have characterized Long COVID across cardiopulmonary, neurological, autonomic, and rehabilitative domains, collectively informing the evidence base for intervention design. The studies below span Phase II trials, platform trials, cohort studies, and pilot investigations, each contributing distinct design parameters and endpoint frameworks.

• HOT-LoCO (NCT04842448): A parallel, randomized, placebo-controlled, double-blind, Phase II trial conducted at a single-centre university hospital in Sweden. 80 subjects (65 women, 15 men) aged 18–60 years with long COVID were randomized 1:1 to 10 sessions of hyperbaric oxygen treatment (HBOT; 100% oxygen, 2.4 bar, 90 min) or sham (placebo medical air, 1.34–1.2 bar) over 6 weeks, stratified by sex and disease severity. Primary endpoints were changes from baseline in RAND-36 Physical Functioning (PF) and Role Limitations due to Physical Health (RP) at 13 weeks, analysed on an intention-to-treat basis. At 13 weeks, no significant difference was observed between HBOT and placebo in PF (LSD 0.63, 95% CI −7.04 to 8.29, p=0.87) or RP (LSD 2.35, 95% CI −5.95 to 10.66, p=0.57).

• RECOVER-AUTONOMIC (NCT06305780): A multicenter, randomized, double-blinded, placebo-controlled platform trial under the NIH RECOVER-CT initiative, evaluating three interventions — coordinated nonpharmacologic care, intravenous immunoglobulin (IVIG), and ivabradine — for postural orthostatic tachycardia syndrome (POTS) in adults with Long COVID. Participants are randomized to IVIG or ivabradine with matching placebo in a factorial design, with or without coordinated nonpharmacologic care. The primary endpoint is change in orthostatic intolerance symptoms measured by the Orthostatic Hypotension Questionnaire/Orthostatic Intolerance Questionnaire from baseline to end of intervention. Secondary endpoints include quality of life, functional performance, symptom burden, and safety; exploratory endpoints include autonomic function testing, wearable sensor data, and longitudinal biomarker profiling.

• LIINC Cardiopulmonary Substudy (NCT04362150): A prospective cohort study with primary analyses conducted as a case-control comparison, enrolling 60 participants (median age 53, 42% female, 87% non-hospitalized) at a median of 17.6 months following SARS-CoV-2 infection. Assessments included cardiopulmonary exercise testing (CPET), cardiac magnetic resonance imaging (CMR), and ambulatory rhythm monitoring. The primary analysis compared peak VO₂ and chronotropic response between those with and without persistent cardiopulmonary symptoms, adjusted for age, sex, BMI, time since infection, and hospitalization status. Among those with symptoms, 18/37 (49%) had reduced exercise capacity (peak VO₂ <85% predicted) versus 3/19 (16%) without symptoms (p=0.02); chronotropic incompetence was present in 11/37 (30%) with symptoms versus 1/19 (5%) without (p=0.04).

• Aerobic Exercise Pilot Study: A single-arm pilot study in which 14 long COVID participants completed twenty 1.5-hour aerobic exercise training sessions over 10 weeks. Outcomes measured before and after training included cardiorespiratory fitness, 6-minute walk distance, quality of life, symptom scores, 7-day physical activity, immunophenotype (CD3+, CD4+, CD19+, CD14++CD16−, CD16++CD14+, CD56+ cells via flow cytometry), and plasma inflammatory biomarkers (TNF-α, IL-6, IL-8, IL-10, INF-γ, INF-λ). Participants significantly increased peak work rate (+16 ± 20 W, p=0.010) and VO₂ peak (+1.55 ± 2.4 mL/kg/min, p=0.030), with reported improvements in fatigue severity (−11%), depression (−42%), anxiety (−29%), and dyspnea level (−46%).

• Intermittent Hypoxia-Hyperoxia Conditioning (IHHC) Cohort Study: An open-label cohort study enrolling 199 post-COVID-19 condition (PCC) patients aged 11–87 years (female-to-male ratio 67:33) experiencing moderate-to-severe fatigue between 1 January 2020 and 31 December 2023. Each patient received a personalized, algorithm-based treatment plan averaging six sessions (range: 2–21), consisting of intermittent hypoxic (9–13% O₂, 3–8 min) and hyperoxic (34–36% O₂, 1–3 min) cycles. Primary outcomes were changes in NRS pain scores and SF-36 quality-of-life scores at 6-week and 6-month follow-ups. SF-36 scores increased by 102 points at 6 weeks (p<0.001, 95% CI: 78.4–127), with improvement persisting at 6 months (Δ106, p<0.001, 95% CI: 57.0–154); pain was reduced by 28–32% at both time points.

• RACHIS Cognitive Cohort Study: A prospective observational study involving a random sample of 138 of 363 PCR-confirmed SARS-CoV-2-positive patients assessed 11 months post-positive PCR test. Participants reporting cognitive symptoms underwent the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MOCA), and Pittsburgh Sleep Quality Index. Cognitive deficits were identified in 5/33 (15.2%) participants via MMSE and 26/33 (78.8%) via MOCA, with notable deficits in visuospatial/executive functions, language repeat, and deferred recall (p<0.001); lower educational level correlated with higher cognitive deficits (p=0.03).

• Mayo Clinic CPET Cohort Study: A retrospective cohort study using the Mayo Clinic exercise testing database, comparing 77 long COVID patients referred from a Post-COVID Care Clinic against 766 historical non-COVID controls with undifferentiated dyspnea on exertion, all without prior cardiac or pulmonary disease. The most prominent CPET finding was lower percent predicted peak V̇O₂ in long COVID patients (73 ± 18% vs 85 ± 23%, p<0.0001). Autonomic abnormalities (resting tachycardia, CNS changes, low systolic blood pressure) were more common in long COVID patients (34% vs 23%, p<0.04).

Targeting Dual Drivers: Persistent Viruses in Long COVID

Several intersecting mechanisms contribute to Long COVID pathogenesis, with viral persistence emerging as a central driver. SARS-CoV-2 RNA and Spike protein have been detected in recovered patients with post-acute sequelae of COVID-19 (PASC) for up to one year or longer after acute infection, with 30% of PASC-positive patients testing positive for both Spike and viral RNA — a finding absent in individuals without PASC. Tissue-level viral persistence extends even further: intracellular SARS-CoV-2 single-stranded spike protein-encoding RNA was identified in rectosigmoid lamina propria tissue in all five examined participants with Long COVID symptoms, and double-stranded spike protein-encoding RNA was detected in three participants up to 676 days after initial infection. Part of the circulating Spike protein is linked to extracellular vesicles, representing a novel mechanism of viral antigen persistence in the absence of intact viral RNA.

Immune dysregulation — particularly T-cell dysfunction — constitutes a second major axis of Long COVID pathophysiology. Whole-body positron emission tomography imaging using the radiopharmaceutical [F]F-AraG demonstrated elevated activated T-lymphocyte tracer uptake in the brain stem, spinal cord, bone marrow, nasopharyngeal and hilar lymphoid tissue, cardiopulmonary tissues, and gut wall in post-acute COVID-19 participants compared with prepandemic controls, with T-cell activation in the spinal cord and gut wall specifically associated with Long COVID symptoms. T-cell exhaustion, characterized by co-expression of inhibitory receptors such as PD-1, TIM-3, and CTLA-4, impaired proliferation, diminished cytokine secretion, and epigenetic dysregulation, is linked to severe disease and persistent symptoms. Reactivation of latent Epstein-Barr virus (EBV) — detected in 72.72% of patients with critical or severe COVID-19 and 67.86% of those with moderate disease — is associated with a diminished CD28 expression and CD28/CD11a co-expression on CD8 T-cells, alongside increased CD57-expressing CD8 T-cells indicative of replicative senescence, pointing to an impaired capacity to control herpesvirus reactivation. HLA immunogenetics further modulate this susceptibility: HLA-A*03 was significantly less frequent in Long COVID patients (10.7% vs. 30.5%, p = 0.001) and associated with a higher percentage of CD8 T-cells and lower expression of inhibitory receptors KIR2DL1 and KIR3DL1, as well as reduced TIGIT expression on NK cells, suggesting a protective immunological phenotype.

At the molecular level, coagulation pathology driven by amyloid fibrin microclots represents a distinct but complementary mechanism. Fibrinogen in the blood of Long COVID patients clots into an anomalous amyloid form of fibrin that is relatively resistant to fibrinolysis, with the resulting microclots capable of blocking capillaries, impairing red blood cell passage, and limiting oxygen exchange — a process proposed to underpin the majority of Long COVID symptoms including fatigue and brain fog. Mechanistically, Spike685 amyloid fibrils (sequence 685–701) induce dense fibrin clot networks and incorporate fibrin into aggregated structures that resist plasmin-mediated fibrinolysis, while Spike601 amyloid fibrils (sequence 601–620) impair thrombin-mediated fibrin formation by binding and sequestering fibrinogen. Antioxidant genetic variants also modulate Long COVID cardiac manifestations: carriers of variant GPX1*T, GPX3*C, or Nrf2*A alleles were more than twice less prone to dyspnea development compared with carriers of the referent alleles (OR = 0.273, p = 0.016), and the variant SOD2*T allele was associated with higher levels of left ventricular echocardiographic parameters EDD, LVMI, and GLS, as well as troponin T (p = 0.038), suggesting subtle left ventricular systolic dysfunction in recovered patients carrying this variant.

Addressing the Critical Unmet Need in Long COVID Treatment

Long COVID remains a condition with no established diagnostic tests and no approved therapies, leaving a growing global patient population dependent on symptom-based supportive care. Estimates place current global prevalence at 6%, with certain subgroups — including women, individuals with comorbidities, and those in nonurban areas — carrying a disproportionate burden. The unmet needs span diagnostic, therapeutic, and population-level gaps, each representing a distinct priority for clinical and strategic investment.

• Absence of validated biomarkers and diagnostic standards. No single laboratory finding is definitively diagnostic for Long COVID. While hormonal markers (cortisol, growth hormone, gonadotropins), metabolomic signals (kynurenine pathway activation, quinolinic acid), and mitochondrial dysfunction indicators have been identified as candidates, evidence remains scattered, hindered by small sample sizes and methodological limitations. Standardization of biomarker assessment and validation in diverse populations are explicitly identified as research priorities.

• No approved pharmacological treatments. Current management focuses exclusively on symptomatic relief and rehabilitation. Investigational approaches — including antiviral agents (nirmatrelvir/ritonavir), immune-modulating therapies, microbiome restoration, and mitochondria-targeted interventions — remain under evaluation. Extended courses of nirmatrelvir/ritonavir (>5 days; range: 7.5–30 days) showed meaningful symptom reduction in some individuals but not others, with no established guidance on optimal course length or patient selection.

• Vulnerable and underserved populations with elevated risk. Women (OR 1.71 [95% CI: 1.17–2.51]), individuals with comorbidities (OR 2.19 [95% CI: 1.56–3.08]), and those with greater acute infection severity (OR up to 7.22 [95% CI: 3.06–17.03] for those presenting to ED/hospitalised) face significantly higher Long COVID risk. Unvaccinated individuals with Long COVID additionally report lower health literacy, lower household income, and reduced trust in institutional information sources, signaling distinct engagement and care-access challenges for this subgroup.

• Patients with persistent, polysymptomatic disease and functional impairment. A polysymptomatic cluster — characterized by worse functioning across work, moderate activity, emotions, and energy — has been identified, with severe acute infection strongly predictive of membership (OR 5.72 [2.04–17.58]). In the second year of illness, 67.6% of patients with post-COVID syndrome did not recover, with objective deficits in neurocognitive performance, handgrip strength (40.2 vs. 42.5 kg in controls), and maximal oxygen consumption (27.9 vs. 31.0 ml/min/kg body weight) persisting without identifiable major pathology on standard laboratory investigation.

• Neurological sequelae as a high-burden, underaddressed domain. Approximately one-third of COVID-19 survivors experience prolonged neurological sequelae persisting for at least 12 months post-infection. Core manifestations — including cognitive impairment, dysautonomia, post-exertional malaise, and depression — overlap substantially with myalgic encephalomyelitis/chronic fatigue syndrome and postural-orthostatic-tachycardia syndrome, yet no neurologically targeted therapy has been established. Collaborative standardization of diagnostic approaches and multimodal therapeutic paradigms are identified as critical needs.

• Patients with immune dysregulation as a potential targetable mechanism. Elevated autoantibodies against G protein-coupled receptors, inverted CD4:CD8 T-cell ratios, CD8 T cell-monocyte complexes, and spontaneous IFNγ release have been documented in Long COVID patients unresponsive to standard multidisciplinary care. A single case report of high-dose intravenous immunoglobulin (400 mg/kg/day for 5 consecutive days, followed by maintenance cycles of 500 mg/kg) demonstrated normalization of fatigue scores, neurocognitive recovery, and reduction in immunological markers over one year, suggesting immunomodulation as a rational therapeutic avenue warranting evaluation in selected patients.

Combination Therapies: SHIELD's Place in the Long COVID Pipeline

Several combination therapy strategies have emerged in recent Long COVID trials, targeting proposed disease drivers including viral persistence, herpesvirus reactivation, and systemic inflammation. Evidence ranges from small pilot case series to randomized controlled trials, reflecting the field's early but accelerating clinical development activity.

• IMC-2 plus Paxlovid (nirmatrelvir-ritonavir): A convenience-sample, open-label case series studied 120 days of IMC-2 alone (IO) versus 120 days of IMC-2 combined with 15 days of Paxlovid (IP) in 24 patients with Long COVID. Participants in the IP group reported an average 55.3% (p < 0.0001) greater reduction in fatigue than the IO group on a visual analog scale, with durable clinical benefit observed at 120-, 305-, and 731-day follow-ups. The authors recommend a larger, controlled trial of this combination.

• Nirmatrelvir-ritonavir plus ritonavir placebo-controlled (PAX LC): The Phase 2, double-blind, randomized PAX LC trial (NCT05668091) evaluated 15 days of nirmatrelvir-ritonavir versus placebo-ritonavir in 100 adults with Long COVID across the 48 contiguous US states. The adjusted mean difference in PROMIS-29 Physical Health Summary Score from baseline to day 28 was -0.55 (95% CI -2.32 to 1.21; p=0.54), indicating no statistically significant improvement over placebo-ritonavir. Study drug-related treatment-emergent adverse events were reported in 35 (76%) of 46 participants in the nirmatrelvir-ritonavir group versus 27 (55%) of 49 in the placebo-ritonavir group, predominantly driven by dysgeusia.

• Inhaled nitric oxide plus molecular hydrogen (iNO/iH2): A prospective, open-label, controlled trial in 60 patients with post-COVID-19 syndrome compared combined iNO/iH2 inhalation, iNO monotherapy, and a control group over 10 days (90-minute sessions via nasal cannula; flow rate 4 liters per minute; iH2 concentrations < 4%; iNO 60 ppm). The combination group demonstrated an increase in 6-minute walk test distance and a decrease in reactive oxygen species compared with both the iNO monotherapy and control groups (p < 0.05), with no serious adverse events recorded.

• Ruxolitinib combined with methylprednisolone: Two case reports described immunocompromised patients with follicular lymphoma and persistent post-COVID-19 interstitial pneumonia who had not responded to molnupiravir, Paxlovid, and methylprednisolone. Low-dose ruxolitinib (5 mg, twice daily) added to a gradually reduced methylprednisolone regimen resolved persistent hypoxemia and produced significant absorption of interstitial inflammation within 1–2 months, with concurrent SARS-CoV-2 negativity.

• Fluvoxamine as add-on to standard therapy: Across 12 of 15 meta-analyses reviewed, fluvoxamine used as an add-on to standard therapy for mild to moderate COVID-19 was associated with a 40–70% reduction in mortality, intubation, and hospitalization rates. A prospective open-label randomized controlled trial further showed significantly less viral load and fewer pro-inflammatory cytokines with fluvoxamine versus standard treatment, including reduced subsequent development of neuropsychiatric and pulmonary Long COVID or fatigue.

Long COVID Phase 2: Strategic Endpoint Choices Amidst Complexities

The initiation of PridCor Therapeutics' Phase 2 SHIELD Study for Long COVID represents a critical juncture in the quest for effective treatments for this debilitating condition. Long COVID, a complex multisystem syndrome, continues to impact millions globally, driving significant healthcare costs and productivity losses. The advancement of a randomized, double-blind, placebo-controlled trial evaluating a combination antiviral regimen is a welcome development, signaling a move towards targeted, evidence-based interventions beyond symptomatic relief.

A key strategic decision for PridCor is the selection of the EQ-5D-5L visual analogue scale as the primary endpoint. This patient-reported outcome measure is widely recognized for assessing health-related quality of life and has been shown to correlate with Long COVID symptom and impact tools. However, the literature also presents a nuanced view: studies indicate that while valuable, the EQ-5D-5L may demonstrate less responsiveness than condition-specific measures like the C19-YRSm in Long COVID populations, and its scores can remain relatively constant over several months. This raises a potential risk for the trial, as a less sensitive endpoint might struggle to capture subtle but clinically meaningful improvements, potentially obscuring a true treatment effect.

Despite this, PridCor's commitment to a rigorous trial design for a combination antiviral regimen positions it as an early leader in addressing the underlying pathology of Long COVID. If successful, this approach could redefine the treatment landscape, offering a disease-modifying option where few currently exist. However, the inherent complexity of Long COVID, with its diverse manifestations and uncertain pathophysiology, means that even a well-designed trial faces significant hurdles. The ability of an antiviral regimen to effectively mitigate post-acute sequelae, rather than just acute infection, remains a critical question. The scientific community and patient population will be closely watching the outcomes of this study, hoping for a breakthrough in a condition that continues to pose immense challenges.